TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
View original at seekingalpha.comTransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion Earnings Call Insights: TransMedics Group, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
TransMedics is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidenceMost of the lung centers were waiting to see the FDA approval to start launching into DENOVO
80% confidenceThe makers of that styrofoam box (competitor) is refusing to randomize their technology to TransMedics in ENHANCE Part B trial
80% confidenceThe makers of styrofoam box competitor are refusing to randomize their technology against OCS in ENHANCE Part B
80% confidenceOCS Liver reached 36% of U.S. liver transplant volume in 2025, up from 26% in 2024
80% confidenceAlmost 50% of incremental investment in 2026 is driven by three elements that are transitory by nature
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue
80% confidenceCompany is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceOperating margins are expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting the timing and scale of investments
80% confidenceOCS Liver reached 36% of U.S. liver transplant volume in 2025, up from 26% in 2024
80% confidenceCompany is laser-focused on ensuring successful execution of initiatives throughout 2026
80% confidenceAlmost 50% of incremental 2026 investment is driven by three transitory elements
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceTransMedics delivered 'our best operational performance to date' and achieved results despite external challenges earlier in the year designed to distract and disrupt sustained growth
80% confidenceThe makers of the styrofoam box technology are refusing to randomize their technology against TransMedics in ENHANCE Part B trial
80% confidenceTransMedics achieved its best operational performance to date in Q4 2025 despite external challenges designed to distract and disrupt growth
80% confidenceMost lung centers were waiting to see FDA approval before launching into DENOVO program
80% confidenceLiver market share gains are pure TransMedics execution excellence, period, full stop
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceTransMedics achieved its best operational performance to date despite external challenges earlier in the year designed to distract and disrupt sustained growth
80% confidenceTransMedics achieved our best operational performance to date with these results achieved despite external challenges earlier in the year that were designed to distract and disrupt our sustained and transformational growth
80% confidenceOperating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million, while OUS transplant revenue grew approximately 33% sequentially to $5 million
80% confidenceMost lung centers were waiting to see FDA approval to start launching into DENOVO program
80% confidenceResults were achieved despite external challenges earlier in the year designed to distract and disrupt sustained growth
80% confidenceWe are not seeing competitive dynamic impacting our ability to execute in 2026 and beyond
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidence